Analyst Perspective: Banco Santander (SAN), AstraZeneca (AZN), Eli Lilly (LLY), Essex Property (ESS)
Investment analysts at Citigroup upgraded shares of Banco Santander, S.A. (SAN) from a “Neutral” to a “Buy” rating
Banco Santander provides various banking products and services for individuals and companies.
Shares of AstraZeneca PLC (AZN) were upgraded by investment banking firm Bryan Garnier from a “Neutral” to a “Buy” rating
AstraZenecais a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Equities researchers at Bank of America Merrill Lynch reiterated shares of Eli Lilly and Co. (LLY) with a Buy rating and raised their price target from $101.00 to $108.00, while global investment banking firm Jefferies maintained its Buy rating on the company’s stock and increased its price target from $105.00 to $115.00
Eli Lillyis a global healthcare leader that unites caring with discovery to make life better for people around the world.
Brokerage firm Cantor Fitzgerald upgraded shares of Essex Property Trust Inc. (ESS) from Hold to Buy with a price target of $251.00, while analysts at DA Davidson initiated coverage on the company’s stock with a Neutral rating and a price target of $237.00
Essex Property Trust, Inc. operates as a self-administered and self-managed real estate investment trust in the United States
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer